Hultcrantz, M., Anderson, L. D. J., Anwer, F., Gasparetto, C., Kocoglu, M. H., Lichtman, E. I., … Kaufman, J. L. (2021). Belantamab Mafodotin (Belamaf; GSK2857916) US Expanded Access Program (EAP) for Heavily Pre-Treated Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Characteristics. In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (Vol. 21, pp. S439–S440).

Hultcrantz, Malin, Larry D Jr Anderson, Faiz Anwer, Cristina Gasparetto, Mehmet H. Kocoglu, Eben I. Lichtman, Clifton Mo, et al. “Belantamab Mafodotin (Belamaf; GSK2857916) US Expanded Access Program (EAP) for Heavily Pre-Treated Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Characteristics.” In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 21:S439–40, 2021.

Hultcrantz M, Anderson LDJ, Anwer F, Gasparetto C, Kocoglu MH, Lichtman EI, et al. Belantamab Mafodotin (Belamaf; GSK2857916) US Expanded Access Program (EAP) for Heavily Pre-Treated Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Characteristics. In: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2021. p. S439–40.

Hultcrantz, Malin, et al. “Belantamab Mafodotin (Belamaf; GSK2857916) US Expanded Access Program (EAP) for Heavily Pre-Treated Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Characteristics.” CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol. 21, 2021, pp. S439–40.

Hultcrantz M, Anderson LDJ, Anwer F, Gasparetto C, Kocoglu MH, Lichtman EI, Mo C, Niesvizky R, Lewis E, Li H, Paul S, Petrone S, Kaufman JL. Belantamab Mafodotin (Belamaf; GSK2857916) US Expanded Access Program (EAP) for Heavily Pre-Treated Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Characteristics. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2021. p. S439–S440.